The American Society of Clinical Oncology’s ASCO20 Virtual Scientific Program will feature abstracts from four Big Ten Cancer Research Consortium studies. The program, taking place May 29-31, will feature more than 250 oral abstract presentations and 2,500 poster presentations from 24 disease-based and specialty tracks.
The abstracts featuring Big Ten CRC studies include poster discussions for BTCRC-GYN15-013 and BTCRC-LUN16-081 and posters for BTCRC-AML17-113 and BTCRC-ESO14-012. Read More
May 1, 2020: Since 1978, the Purdue University Center for Cancer Research has been a National Cancer Institute-designated basic research cancer center. Only seven institutions in the United States have earned this title. Being a basic research center means we don’t treat cancer patients directly. Our work focuses on investigating cancers where they begin — at the cellular level — to investigate the cause of and cure for one of the most devastating diseases of our time. Doctors and scientists throughout the world use our discoveries to develop methods, medicines, and medical devices to save and enhance patients’ lives. Learn more at: https://www.purdue.edu/cancer-research/. Investigator... Read More
April 22, 2020: In this month’s Across the Consortium, the Big Ten Cancer Research Consortium (Big Ten CRC) highlights the tireless work of researchers to develop new therapies to kill cancer. Despite the difficult times our world is facing, we are grateful that our member institutions are finding creative ways to continue the fight against cancer. Read More
April 13, 2020: The Big Ten Cancer Research Consortium recently appointed Kari B. Wisinski, MD, associate professor of hematology/oncology, Department of Medicine at University of Wisconsin School of Medicine and Public Health, as chair of the consortium’s Steering Committee. She succeeds Al B. Benson III, MD, professor of medicine-hematology/oncology at Northwestern University Feinberg School of Medicine, who completed his one-year term. Peter G. Shields, MD, deputy director, The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James), will serve as vice chair of the Steering Committee for one year and as chair the following year. Read More
March 18, 2020: In this month’s Across the Consortium, the Big Ten Cancer Research Consortium (Big Ten CRC) highlights new tests and genomic research that could help identify cancer earlier in its development. We also congratulate those who received awards for their research, and we remember champions of cancer research who recently passed away. Read More
March 17, 2020: Christopher Lao, MD, was recently appointed to represent the University of Michigan Rogel Cancer Center on the Big Ten Cancer Research Consortium Steering Committee. Dr. Lao is clinical professor of internal medicine – hematology/oncology, and medical director of clinical trials for oncology at the University of Michigan. The Steering Committee is composed of one researcher from each Big Ten CRC member institution and meets on a regular basis to review activities of the consortium and decide matters of policy. The Steering Committee determines the criteria for approving concepts for development with the Big Ten CRC. Read More
March 1, 2020:Investigator SpotlightAnita Turk, MD, Indiana University School of Medicine Educational background MD: Indiana University School of Medicine Residency: University of Chicago Fellowship: University of Wisconsin Research interests I am a medical oncologist who treats gastrointestinal malignancies with a special focus on hepatobiliary cancers. My research focus is to develop targeted and immune-based therapies for my patients. Through Indiana University's Precision Genomics Clinic, we have been able to sequence tumors to help us understand the biology and identify the best clinical trials within the Big Ten... Read More
Feb. 26, 2020: Results of a Big Ten Cancer Research Consortium study found that the combination of pembrolizumab and bevacizumab is safe and active in patients with metastatic kidney cancer and was published online in the Journal of Clinical Oncology on Feb. 25. The multi-site phase Ib/II study of pembrolizumab with bevacizumab for metastatic renal cell carcinoma: Big Ten Cancer Research Consortium BTCRC-GU14-003, was led by Arkadiusz Z. Dudek, MD (pictured), a professor in the Division of Hematology/Oncology, Department of Medicine, at the University of Illinois at Chicago, and medical oncologist at HealthPartners Regions... Read More
February. 20, 2020: In this month’s Across the Consortium, the Big Ten Cancer Research Consortium (Big Ten CRC) highlights new treatments and discoveries our members are making to bring us one step closer to defeating cancer. We also recognize those who have experienced cancer firsthand and are now dedicating their time and passion to fight for a cure. Read More
Feb. 14, 2020: Monika Joshi, MD, MRCP, associate professor of medicine at Penn State Hershey Cancer Institute, will present a poster that highlights early safety and efficacy data from the Big Ten Cancer Research Consortium’s BTCRC-GU15-023 study during the American Society of Clinical Oncology’s 2020 Genitourinary Cancers Symposium on Feb. 14 in San Francisco, Calif. The poster, titled, “Concurrent durvalumab and radiation therapy followed by adjuvant durvalumab in patients with locally advanced urothelial cancer of the bladder (DUART),” will be presented during Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral,... Read More
Subscribe to the Big Ten CRC Newsletter
X
Facebook
YouTube